Comparative Pharmacology
Head-to-head clinical analysis: LOW QUEL versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW QUEL versus OGESTREL 0 5 50 21.
LOW-QUEL vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
10 mg orally twice daily; not to exceed 20 mg/day.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (CrCl 30-50 mL/min).
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive